Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.52 |
| ▸ | DHPS | P49366 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696630 | 0.80 | HTR6 (0.55) | HTR6LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL17111036 | 0.80 | HTR6 (0.55) | HTR6LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL29809414 | 0.79 | ACHE (0.59) | EGLN1DHPSMAPK14LMNAKDM4E | |
| SCHEMBL1757848 | 0.79 | ACHE (0.59) | EGLN1DHPSMAPK14LMNAKDM4E | |
| SCHEMBL4147543 | 0.78 | PARP1 (0.62) | HTR6EGLN1DHPSMAPK14LMNA | |
| SCHEMBL4056966 | 0.77 | HTR6 (0.60) | HTR6KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL29880153 | 0.77 | HTR6 (0.60) | HTR6KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1774558 | 0.77 | HTR6 (0.49) | HTR6LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL1775925 | 0.75 | HTR6 (0.62) | HTR6LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL10269146 | 0.75 | HTR6 (0.61) | HTR6LMNAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-03-28 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | HTR6 989/4885EGLN1 2949/4885DHPS 11/4885 |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | HTR6 989/4885EGLN1 2949/4885DHPS 11/4885 |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | HTR6 963/4885EGLN1 2695/4885DHPS 17/4885 |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | PSAP, ABCG2, PSAT1 | HTR6 429/4885EGLN1 1186/4885DHPS 7/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | HTR6 963/4885EGLN1 2695/4885DHPS 17/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | HTR6 963/4885EGLN1 2695/4885DHPS 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.